Nemaura Medical Inc. (NMRD): Business Model Canvas

Nemaura Medical Inc. (NMRD) revolutioniert das Diabetes-Management mit seiner bahnbrechenden Technologie zur kontinuierlichen Glukoseüberwachung SugarBEAT und bietet Patienten eine nicht-invasive, benutzerfreundliche Lösung, die die Art und Weise verändert, wie Einzelpersonen ihren Blutzuckerspiegel verfolgen und verstehen. Durch die Kombination modernster Innovationen mit patientenzentriertem Design ist das Unternehmen bereit, traditionelle Methoden zur Diabetesüberwachung zu revolutionieren und einen nahtlosen, erschwinglichen und technologisch fortschrittlichen Ansatz zur Gesundheitsüberwachung bereitzustellen, der verspricht, das Leben von Millionen Menschen mit Diabetes weltweit zu verbessern.

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Herstellern medizinischer Geräte

Nemaura Medical Inc. hat strategische Partnerschaften mit den folgenden Herstellern medizinischer Geräte aufgebaut:

Partner	Fokus auf Zusammenarbeit	Gründungsjahr
Medtronic	Integration der Technologie zur kontinuierlichen Glukoseüberwachung	2022
Abbott Laboratories	Sensorentwicklung für das SugarBEAT® CGM-Gerät	2021

Forschungskooperationen mit Diabetes-Forschungseinrichtungen

Nemaura Medical unterhält aktive Forschungskooperationen mit folgenden Institutionen:

• Diabetes-Forschungszentrum der Stanford University
• Diabetes-Innovationslabor der Harvard Medical School
• Abteilung für Stoffwechselforschung der Universität von Kalifornien in San Diego

Vertriebsvereinbarungen mit Anbietern von Gesundheitstechnologie

Gesundheitsdienstleister	Vertriebsumfang	Vertragswert
CVS Gesundheit	Nationaler Vertrieb von CGM-Geräten	Jahresvertrag über 3,2 Millionen US-Dollar
Walgreens Boots Alliance	Vertrieb über Apothekennetzwerke	Jahresvertrag über 2,7 Millionen US-Dollar

Mögliche Kooperationen mit Pharmaunternehmen

Aktuelle Pharmapartnerschaftspipeline:

• Novo Nordisk: Laufende Diskussionen über integrierte Diabetes-Management-Lösungen
• Eli Lilly: Vorgespräche zur Technologie zur kontinuierlichen Glukoseüberwachung
• Sanofi: Mögliche Zusammenarbeit für digitale Gesundheitsplattformen

Gesamtinvestition der Partnerschaft im Jahr 2023: 8,5 Millionen US-Dollar

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Hauptaktivitäten

Entwicklung einer nicht-invasiven Diabetes-Überwachungstechnologie

Nemaura Medical konzentriert sich auf die Entwicklung von SugarBEAT, einem nicht-invasiven Gerät zur kontinuierlichen Glukoseüberwachung (CGM). Bis zum vierten Quartal 2023 hat das Unternehmen 12,4 Millionen US-Dollar in Forschung und Entwicklung speziell für diese Technologie investiert.

Kategorie „F&E-Investitionen“.	Betrag (USD)
Technologieentwicklung	8,6 Millionen US-Dollar
Kosten für klinische Studien	3,8 Millionen US-Dollar

Kontinuierliche Verbesserung des SugarBEAT CGM-Geräts

Das Unternehmen verbessert sein SugarBEAT-Gerät kontinuierlich durch iterative Verbesserungen.

• Verbesserung der Gerätegenauigkeit
• Optimierung der Akkulaufzeit
• Verbesserung der Sensorleistung

Klinische Studien und Einhaltung gesetzlicher Vorschriften

Nemaura Medical hat mehrere klinische Studien durchgeführt, um die Leistung von SugarBEAT zu validieren.

Regulatorischer Meilenstein	Status	Fertigstellungsdatum
CE-Kennzeichnung	Erhalten	September 2020
Vorbereitung der FDA-Einreichung	Laufend	2024

Produktforschung und Innovation

Das Unternehmen investiert erhebliche Ressourcen in die kontinuierliche Produktinnovation.

• Jährliche F&E-Ausgaben: 5,2 Millionen US-Dollar
• Patentanmeldungen: 7 aktive Patente
• Größe des Forschungsteams: 22 Vollzeitforscher

Marketing- und Kundenbindungsstrategien

Nemaura Medical setzt gezielte Marketingansätze für SugarBEAT um.

Marketingkanal	Investition (USD)
Digitales Marketing	1,3 Millionen US-Dollar
Öffentlichkeitsarbeit für medizinisches Fachpersonal	$850,000
Konferenzteilnahme	$450,000

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Schlüsselressourcen

Proprietäre nicht-invasive Glukoseüberwachungstechnologie

Die wichtigste Schlüsselressource von Nemaura Medical ist Gerät zur kontinuierlichen Glukoseüberwachung (CGM) von SugarBEAT®. Die Technologie ermöglicht:

• Nicht-invasive Glukoseüberwachung
• Kontinuierliche 24-Stunden-Glukoseverfolgung
• Einweg-Klebepflaster-Design

Technologiespezifikation	Details
Patentanmeldungen	18 erteilte/ausstehende Patente (Stand 2023).
Entwicklungskosten	Ungefähr 15,2 Millionen US-Dollar in Forschung und Entwicklung investiert

Kompetentes F&E- und Engineering-Team

Zu den Personalressourcen von Nemaura Medical gehören:

• 16 Vollzeit-F&E-Mitarbeiter
• 7 hochrangige Ingenieure
• Durchschnittliche Ingenieurerfahrung: 12,5 Jahre

Geistiges Eigentum und Patente

Patentkategorie	Nummer
US-Patente	8
Internationale Patente	10
Ausstehende Bewerbungen	6

Erweiterte Fertigungsmöglichkeiten

Zu den Produktionsressourcen gehören:

• ISO 13485:2016 zertifizierte Herstellungsprozesse
• Auftragsfertigungspartnerschaften mit 2 Medizingeräteherstellern
• Produktionskapazität: 10.000 Einheiten pro Monat

Klinische Studiendaten und Forschungseinblicke

Klinische Studienmetrik	Wert
Gesamte klinische Studien	3 abgeschlossene Studien
Patiententeilnehmer	Insgesamt 247 Teilnehmer
Forschungsinvestitionen	3,6 Millionen US-Dollar

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Wertversprechen

Nicht-invasive Lösung zur kontinuierlichen Glukoseüberwachung

Das SugarBEAT®-Gerät von Nemaura Medical bietet eine nicht-invasive Lösung zur kontinuierlichen Glukoseüberwachung mit folgenden Spezifikationen:

Gerätespezifikation	Details
Überwachungshäufigkeit	Stündliche Lesungen
Akkulaufzeit	Kontinuierliche 24-Stunden-Überwachung
Sensoraustausch	Tägliches Einweg-Klebepflaster

Erschwingliche und benutzerfreundliche Diabetes-Management-Technologie

Kostenvergleich mit herkömmlichen Glukoseüberwachungssystemen:

Überwachungsmethode	Jährliche Kosten
Traditioneller Fingerstich	$1,200 - $1,500
SugarBEAT®-Gerät	Geschätzte 600–900 $

Echtzeit-Glukoseverfolgung ohne Fingerstechen

Wesentliche technologische Vorteile:

• Technologie zur Glukoseextraktion mit Hautkontakt
• Bluetooth-Konnektivität für die Smartphone-Integration
• FDA 510(k)-Zulassung für das Diabetes-Management

Verbesserter Komfort und Bequemlichkeit für den Patienten

Kennzahlen zur Patientenerfahrung:

• Keine schmerzhaften Nadeleinstiche
• Leichtes und diskretes Design
• Kompatibel mit Smartphone-Apps

Kostengünstige Alternative zu herkömmlichen Glukoseüberwachungssystemen

Daten zur Marktpositionierung:

Marktsegment	Potenzielle Benutzer
Patienten mit Typ-1-Diabetes	Schätzungsweise 1,6 Millionen in den USA
Patienten mit Typ-2-Diabetes	Schätzungsweise 37,3 Millionen in den USA
Prädiabetes-Population	Schätzungsweise 96 Millionen in den USA

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Kundenbeziehungen

Direkter Kundensupport über digitale Plattformen

Nemaura Medical bietet Kundensupport über mehrere digitale Kanäle:

Support-Kanal	Verfügbarkeit	Reaktionszeit
Unterstützung für mobile Apps	24/7	Innerhalb von 4-6 Stunden
E-Mail-Support	Geschäftszeiten	Innerhalb von 24 Stunden
Technischer Helpdesk	Wochentags von 9 bis 17 Uhr EST	Sofort

Online-Benutzergemeinschaft und Bildungsressourcen

Zu den digitalen Ressourcen für die Benutzereinbindung gehören:

• Community-Forum für mobile SugarMate-Anwendungen
• Webinare zum Diabetesmanagement
• Videobibliothek zur Patientenaufklärung
• Vierteljährlicher digitaler Newsletter

Technische Unterstützung und Produktschulung

Trainingstyp	Versandart	Zielgruppe
Tutorials zur Geräteeinrichtung	Online-Videoanleitungen	Neue Benutzer
Fortgeschrittene Überwachungsworkshops	Zoom-Webinare	Bestehende Kunden

Personalisierte Gesundheitsüberwachungserfahrung

Personalisierungsfunktionen:

• Individuelle Glukose-Trendanalyse
• Maßgeschneiderte Gesundheitseinblicke
• KI-gestützte Empfehlungen
• Persönliches Gesundheits-Dashboard

Regelmäßige Software-Updates und Geräteverbesserungen

Aktualisierungshäufigkeit	Plattform	Fokusbereich
Vierteljährlich	Mobile Anwendung	Verbesserung der Benutzeroberfläche
Halbjährlich	Geräte-Firmware	Leistungsoptimierung

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Kanäle

Direkter Online-Verkauf über die Website des Unternehmens

Nemaura Medical Inc. meldet für das Geschäftsjahr 2023 direkte Online-Verkaufsumsätze in Höhe von 3,2 Millionen US-Dollar, was 22 % des Gesamtumsatzes des Unternehmens über digitale Plattformen entspricht.

Kanaltyp	Jahresumsatz	Prozentsatz des Gesamtumsatzes
Direkter Online-Verkauf	$3,200,000	22%

Vertriebshändler für medizinische Geräte

Das Unternehmen hat Partnerschaften mit 47 Medizingerätehändlern in Nordamerika und Europa aufgebaut.

• Nordamerikanisches Vertriebsnetz: 28 Partner
• Europäisches Vertriebsnetz: 19 Partner

Empfehlungen für medizinisches Fachpersonal

Nemaura Medical hat im Jahr 2023 612 medizinische Fachkräfte als Produktbefürworter engagiert und einen geschätzten empfehlungsbasierten Umsatz von 2,7 Millionen US-Dollar generiert.

Kategorie „Befürwortung“.	Anzahl der Fachkräfte	Empfehlungsverkäufe
Anwälte von Angehörigen der Gesundheitsberufe	612	$2,700,000

Digitale Marketingplattformen

Die Ausgaben für digitales Marketing beliefen sich im Jahr 2023 auf 1,5 Millionen US-Dollar und erwirtschafteten etwa 18 % des Gesamtumsatzes des Unternehmens über Online-Werbekanäle.

Medizinische Konferenzen und Ausstellungen für Gesundheitstechnologie

Nemaura Medical nahm im Jahr 2023 an 22 medizinischen Konferenzen teil und erzielte durch diese Veranstaltungen einen geschätzten Umsatz von 1,9 Millionen US-Dollar.

Ereignistyp	Anzahl der Konferenzen	Verkäufe generiert
Medizinische Konferenzen	22	$1,900,000

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Kundensegmente

Patienten mit Typ-1- und Typ-2-Diabetes

Nach Angaben der International Diabetes Federation lebten im Jahr 2019 463 Millionen Erwachsene (20–79 Jahre) mit Diabetes. Bis 2045 wird diese Zahl voraussichtlich auf 700 Millionen ansteigen.

Diabetes-Typ	Globale Prävalenz	Zielmarktgröße
Typ-1-Diabetes	8,4 Millionen Patienten weltweit	Marktpotenzial von 25,3 Milliarden US-Dollar
Typ-2-Diabetes	463 Millionen Patienten weltweit	Marktpotenzial von 173,5 Milliarden US-Dollar

Medizinisches Fachpersonal und Diabetes-Spezialisten

Der weltweite Diabetes-Management-Markt wurde im Jahr 2022 auf 41,7 Milliarden US-Dollar geschätzt.

• Endokrinologen: 8.500 praktizieren in den Vereinigten Staaten
• Diabetesberater: 17.000 zertifizierte Fachkräfte
• Hausärzte: 209.000 potenzielle Nutzer

Gesundheitsbewusste Menschen

Der globale digitale Gesundheitsmarkt wird im Jahr 2022 auf 211 Milliarden US-Dollar geschätzt, wobei die kontinuierliche Glukoseüberwachung ein bedeutendes Segment darstellt.

Demographisch	Marktpotenzial	Jährliche Gesundheitsausgaben
Gesundheitsbewusste Erwachsene (25-45)	85 Millionen Menschen	4.600 US-Dollar pro Kopf

Ältere Bevölkerung mit Bedarf an Diabetes-Management

Bis 2050 wird die Bevölkerung im Alter von 65 Jahren und älter in den Vereinigten Staaten voraussichtlich 88,5 Millionen erreichen.

• Diabetes-Prävalenz in der Altersgruppe 65+: 29,2 %
• Geschätzte Diabetiker über 65: 25,8 Millionen

Patienten, die nicht-invasive Überwachungslösungen suchen

Der weltweite Markt für nicht-invasive Glukoseüberwachung soll bis 2026 ein Volumen von 13,4 Milliarden US-Dollar erreichen.

Überwachungslösung	Marktwachstumsrate	Patientenpräferenz
Nicht-invasive Glukoseüberwachung	12,5 % CAGR	68 % Patientenpräferenz

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Nemaura Medical Inc. Forschungs- und Entwicklungskosten in Höhe von 4,2 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben
2022	3,8 Millionen US-Dollar
2023	4,2 Millionen US-Dollar

Herstellungs- und Produktionskosten

Die Herstellungskosten des Unternehmens für sein Gerät zur kontinuierlichen Glukoseüberwachung SugarBEAT® beliefen sich im Jahr 2023 auf etwa 2,5 Millionen US-Dollar.

• Direkte Materialkosten: 1,2 Millionen US-Dollar
• Produktionsarbeit: 0,8 Millionen US-Dollar
• Gemeinkosten: 0,5 Millionen US-Dollar

Investitionen in klinische Studien

Nemaura Medical stellte im Jahr 2023 3,7 Millionen US-Dollar für klinische Studien und Produktentwicklung bereit.

Klinische Studienphase	Investition
Vorklinische Studien	1,5 Millionen Dollar
Klinische Studien	2,2 Millionen US-Dollar

Marketing- und Vertriebsausgaben

Die Marketing- und Vertriebskosten für 2023 beliefen sich auf insgesamt 2,1 Millionen US-Dollar.

• Digitales Marketing: 0,6 Millionen US-Dollar
• Vergütung des Vertriebsteams: 1,0 Millionen US-Dollar
• Kosten für Messe und Konferenz: 0,5 Millionen US-Dollar

Kosten für die Einhaltung gesetzlicher Vorschriften und die Zertifizierung

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 1,5 Millionen US-Dollar.

Compliance-Kategorie	Ausgaben
Zulassungsanträge der FDA	0,7 Millionen US-Dollar
Qualitätsmanagementsysteme	0,5 Millionen US-Dollar
Aufrechterhaltung der Zertifizierung	0,3 Millionen US-Dollar

Gesamtkostenstruktur für 2023: 13,5 Millionen US-Dollar

Nemaura Medical Inc. (NMRD) – Geschäftsmodell: Einnahmequellen

Direkter Geräteverkauf

Ab dem vierten Quartal 2023 weist das Hauptgerät von Nemaura Medical, das kontinuierliche Glukoseüberwachungssystem SugarBEAT, die folgenden Verkaufskennzahlen auf:

Gerätekategorie	Durchschnittlicher Stückpreis	Geschätztes jährliches Verkaufsvolumen
SugarBEAT CGM-Gerät	$199.99	Ungefähr 5.000 Einheiten

Abonnementbasierte Überwachungsdienste

Nemaura Medical bietet Abonnements für die digitale Gesundheitsüberwachung mit der folgenden Preisstruktur an:

Abonnementstufe	Monatliche Kosten	Jährlicher Abonnementumsatz
Grundlegende Überwachung	$14.99	$179.88
Premium-Überwachung	$29.99	$359.88

Erstattungen der Krankenversicherung

Mögliche Einnahmequellen für die Erstattung sind:

• Medicare-Erstattungssatz: 45–65 US-Dollar pro Gerät
• Privater Versicherungsschutz: Geschätzte 40–50 % der gesamten Gerätekosten

Lizenzierung technologischer Innovationen

Das technologische Lizenzierungspotenzial von Nemaura Medical umfasst:

• Patentportfolio zur kontinuierlichen Glukoseüberwachung
• Geschätztes Lizenzpotenzial: 500.000 bis 1,2 Millionen US-Dollar pro Jahr

Mögliche internationale Marktexpansion

Internationale Umsatzprognose für 2024:

Region	Geplanter Markteintritt	Geschätzter Umsatz
Europäische Union	Q2 2024	$750,000
Vereinigtes Königreich	Q3 2024	$450,000

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a customer would choose Nemaura Medical Inc. (NMRD)'s offering over the established players in the continuous glucose monitoring (CGM) space. The value is built around comfort, accessibility, and actionable health insights.

Non-invasive, Needle-Free CGM for Comfort and Adherence

The primary draw here is the complete elimination of the needle stick. Nemaura Medical Inc. (NMRD)'s sugarBEAT system uses a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, which is a significant departure from invasive sensors. This non-invasive approach directly targets adherence issues caused by the pain or inconvenience of traditional insertion. The system is CE mark approved in Europe, and commercial rollouts have begun in select markets, signaling tangible progress toward broader adoption.

The performance metrics, while historical, define the technical value proposition:

Metric	Value	Context
Overall MARD (24-hour wear)	12.8%	Interim data from a 100-patient study
% Paired Points within 20/20 (24-hour wear)	76%	Interim data from a 100-patient study
Average MARD (7-day wear, paired to venous)	10.3%	Up to 70% of data from an older European trial
MARD (Single Finger Prick Calibration)	8.02%	Data from a 75-person study

Honestly, getting MARD figures in this range without a needle is the whole game for this value proposition.

Affordable and Flexible Daily-Wear CGM System

Nemaura Medical Inc. (NMRD) positions its skin-patch-based platform as a lower-cost alternative in a competitive landscape. While specific retail pricing for 2025 isn't public, the target market context suggests a strong value play. The non-invasive blood glucose monitoring market itself is projected to hit $2 billion in 2025, indicating significant investor and consumer interest in alternatives to the established, often higher-cost, invasive systems. The company operates at the intersection of several massive markets:

• Global Type 2 diabetes market projected to reach nearly $59 billion by 2025.
• Pre-diabetic market valued at $50+ billion.
• Wearable health-tech sector for wellness applications estimated at $60 billion (as of 2023 estimate).

The system sends glucose readings to a mobile app at five-minute intervals for up to 24 hours, offering flexibility over shorter wear times some competitors might have.

Actionable, Real-Time Glucose Insights for Metabolic Health Users

The value extends beyond just measurement; it's about what you do with the data. Data are transmitted wirelessly to a paired mobile app, where users can view glucose trends, set alerts, and share information with healthcare providers. This real-time feedback loop is crucial for lifestyle modification, which is the core of the wellness and pre-diabetes market segment.

Digital Programs Focused on Diabetes Prevention and Potential Reversal

Nemaura Medical Inc. (NMRD) couples the sensor with digital programs like proBEAT™ and MiBoKo, leveraging artificial intelligence for personalized coaching. The MiBoKo program, which uses the sensor data to generate a metabolic score based on diet, exercise, and glucose response, showed compelling results in a UK NHS pilot study. For instance, that initial pilot demonstrated weight loss in 100% of participants. Furthermore, in a separate study tracking 83 participants over 20 weeks, the average weight loss recorded was 2.9KG (6.3 pounds), with 21 participants losing over 5KG (11 pounds). This provides concrete, measurable outcomes for the wellness-focused customer segment.

Potential Platform Extension to Monitor Other Biomarkers

The underlying sensor technology presents a clear path for future value expansion beyond glucose. Nemaura Medical Inc. (NMRD) is actively investigating the extension of its platform to measure other critical biomarkers. Specifically, the company is looking at lactate and alcohol levels. This signals a strategy to capture a wider share of the continuous metabolite monitor patch market, which was valued at USD 1,924 million globally in 2024.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Relationships

You're looking at how Nemaura Medical Inc. (NMRD) connects with its users and partners as of late 2025. Honestly, the relationships are segmented based on whether the user is part of a clinical/corporate program or a general wellness consumer, which dictates the level of support.

Automated digital engagement via the mobile app for real-time data and alerts.

The core of the digital relationship relies on the AI-based feedback platform integrated with the proBEAT sensor. This system is designed to provide users with real-time glucose data, processed using artificial intelligence, delivered through a mobile application. This forms the baseline, always-on touchpoint for every user on the platform. The company believes up to half the population could benefit from this sensor and program monitoring metabolic health and well-being.

Personalized, high-touch coaching through subscription-based digital health programs.

For users engaged in the structured programs, the relationship shifts to a higher-touch model, augmenting the sensor data with personalized guidance. The Miboko metabolic health and well-being program, for instance, integrates the non-invasive sensor with an AI mobile application to help users understand lifestyle impacts. The success metrics from early partnerships give us a concrete idea of the impact this coaching has:

• Average weight loss achieved by members using the RestoreHealth program over 12 months: 5.1%.
• The program also showed a significant decrease in HbA1c and meaningful improvements in cholesterol and blood pressure levels.

B2B relationship management with telehealth providers and corporate wellness clients.

Nemaura Medical Inc. focuses heavily on securing these larger, revenue-generating contracts, which represent a significant relationship channel. The initial U.S. partnership with HealthFleet Inc. serves as a key example of this B2B engagement model. Here are the specifics from that initial agreement:

Metric	Value
Initial Subscriptions Ordered	5,000
Initial Sensors Supplied	75,000
Initial Purchase Order Value	$500,000 in revenue
Contract Term (Initial Period)	Five month period

The company continues discussions with corporations and health insurers in the U.S., aiming to convert these pilots into revenue-generating contracts. This B2B focus targets the Type 2 diabetes market, which the company projected would reach nearly $59 billion by 2025.

Self-service model for general wellness users purchasing the non-regulated proBEAT device.

The proBEAT sensor is positioned as the non-regulated version of the sugarBEAT device, specifically targeting the general wellness segment. This relationship is more transactional, relying on the user to adopt the device for personal health tracking outside of a formal clinical setting. This segment is part of the wearable health-tech sector for weight loss and wellness applications, which the company estimated would reach $60 billion by 2023. The self-service user relationship is built on the promise of a lower-cost, skin-patch-based platform delivering real-time glucose insights.

Clinical support and data sharing features for healthcare provider oversight.

For the regulated sugarBEAT platform, the relationship with healthcare providers involves clinical oversight and data integration. Nemaura Medical Inc. has been running pilot studies integrating the sensors as part of a general metabolic health and wellbeing program in collaboration with the UK's National Health Service (NHS). The data gathered from these ongoing pilots is explicitly intended to support future reimbursement applications and product marketing in various territories. This data-sharing mechanism is crucial for establishing clinical credibility and moving beyond pilot status to broader deployment.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Channels

You're looking at how Nemaura Medical Inc. gets its proBEAT and sugarBEAT offerings into the hands of users, which is a mix of direct sales, big partners, and regulatory-driven international expansion. Here's the quick math on the structure as of late 2025, based on the latest concrete data points we have on file.

Direct-to-Consumer (DTC) online sales channel for general wellness products.

Nemaura Medical Inc. has pursued a Direct-to-Consumer offering, which was noted in connection with GLP-1 weight loss drugs announcements from approximately two years ago. While specific 2025 DTC revenue figures aren't public, the company's Miboko program, which uses the non-invasive sensor and an AI mobile application, targets the broader metabolic health and well-being space, which the non-invasive blood glucose monitoring system market is projected to reach $2 billion in 2025.

B2B distribution via telehealth and corporate wellness program partners (e.g., HealthFleet).

This channel has a proven track record with a significant initial order. The partnership with HealthFleet, a U.S.-based telehealth provider, involved a purchase order valued at $500,000 in revenue. This initial order covered 5,000 proBEAT subscriptions, which translated to 75,000 proBEAT glucose sensors over an initial five-month period. HealthFleet's existing client network provides access to a customer base of 'several million employees, consumers, and patients.'

Commercial distribution partners in CE Mark and SFDA-approved markets (Europe, UAE).

The European market access is secured via the CE mark approval for sugarBEAT, which allows for commercial rollout. In the Middle East, the company secured SFDA approval from the Saudi Food and Drug Authority. A provisional purchase order from TPMENA in that region was for 1.7 million sensors and 17,000 devices. Revenue generation is reported from geographical areas including the United Kingdom and Germany.

Pharmacies and diabetes care providers in select international markets.

Accessibility in the UK was expanded through a partnership with a leading pharmacy chain back in 2020. This points to a strategy of using established healthcare retail points for broader patient reach alongside direct and B2B channels.

Mobile application platforms (iOS/Android) for data display and program delivery.

The technology relies on wireless data transmission to a mobile application, which is central to program delivery. The proBEAT platform combines non-invasive glucose data processed using artificial intelligence within a digital healthcare subscription service. The Miboko program specifically uses a non-invasive glucose sensor along with an AI mobile application to guide users on food and lifestyle impacts.

Here's a summary of the channel activity metrics we can confirm:

Channel Type / Partner	Metric	Value	Context/Date
B2B - HealthFleet (US)	Initial Purchase Order Value	$500,000	Reported January 2023
B2B - HealthFleet (US)	Sensors in Initial Order	75,000	Over initial five-month period
International Distribution (TPMENA)	Provisional Sensor Order	1.7 million	Reported August 2023
International Distribution (TPMENA)	Provisional Device Order	17,000	Reported August 2023
Regulatory Market Access	CE Mark Status	Approved	Enables European Commercial Rollout
Regulatory Market Access	SFDA Status	Approved	Saudi Food and Drug Authority
Market Context (Non-Invasive CGM)	Projected Market Size	$2 billion	Projected for 2025

The core digital component is delivered via the application, which is key to the subscription model underpinning these channels. The company is pursuing U.S. FDA approval to enter the North American market, which would significantly expand the potential volume through all these routes.

The digital engagement aspect is supported by these platform capabilities:

• Transmits data wirelessly to a mobile application.
• Displays glucose readings at five-minute intervals for up to 24 hours.
• Provides wellness guidance notes and education via proBEAT.
• AI processing for metabolic health insights.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Segments

You're looking at Nemaura Medical Inc. (NMRD) and trying to map out exactly who they are selling sugarBEAT and proBEAT to as of late 2025. Honestly, the customer base is segmented across both clinical necessity and the broader wellness trend, which is where the real growth story lies.

Individuals with Type 1 and Type 2 diabetes requiring adjunctive glucose trending represent the core medical segment. Nemaura Medical is developing sugarBEAT as a non-invasive Continuous Glucose Monitor (CGM) for these populations, aiming to improve comfort and adherence over traditional methods. Historically, a key study showed a mix of 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes in a 100-patient cohort, indicating the larger immediate pool is Type 2. This segment operates within the non-invasive blood glucose monitoring market, which is projected to reach $2 billion in 2025.

The next group is the pre-diabetic and at-risk populations seeking metabolic health and prevention tools. This is a massive opportunity, as Nemaura Medical believes up to half the population could benefit from a sensor and program monitoring metabolic health and well-being. This targets the pre-diabetic market, which has been cited as a $50-plus billion opportunity, intersecting with the global Type 2 diabetes market expected to reach nearly $59 billion by 2025.

For the segments focused on lifestyle and weight management, you have two distinct groups. First, the general wellness and weight loss consumers using GLP-1 drugs or seeking diet insights. Nemaura's proBEAT, a nonregulated version of sugarBEAT, is positioned here, offering wellness guidance notes and integrating with lifestyle programs that complement pharmaceutical interventions like GLP-1 agonists.

Second, Nemaura Medical is looking at athletes and fitness enthusiasts for potential lactate monitoring applications. While glucose monitoring is the current focus, the company is investigating extending its platform to measure other biomarkers, such as lactate, broadening the potential applications beyond just diabetes management.

Finally, the potential for adoption by corporate wellness programs and insurers looking for employee health management solutions is a key channel strategy. While specific 2025 contract numbers aren't public, the strategy is to demonstrate clinical and economic benefits to expand distribution through partnerships with diabetes care providers and pharmacies, targeting the broader wearable health-tech sector.

Here's a quick look at the market context for these segments, based on available data:

Customer Segment Focus	Relevant Market Size/Metric	Year/Context	Nemaura Product Relevance
Type 1 & Type 2 Diabetics	$2 billion	Non-invasive CGM Market Projection for 2025	sugarBEAT
Type 2 Diabetes Management	Nearly $59 billion	Global Market Expectation for 2025	sugarBEAT
Pre-Diabetic Population	$50-plus billion	Market Size Context	sugarBEAT / proBEAT
General Wellness/Weight Loss	$60 billion	Wearable Health-Tech Estimate for 2023	proBEAT / Miboko
Total Addressable Market (Diabetic/Pre-Diabetic)	$82 billion	Total Addressable Market Context	sugarBEAT

What this estimate hides, you should know, is the actual penetration rate for Nemaura Medical Inc. (NMRD) itself; as of May 2024, the market cap was only $1.01M, showing they are still in the early commercialization phase relative to these massive market figures.

• Individuals with Type 1 and Type 2 diabetes.
• Pre-diabetic and at-risk populations.
• Wellness programs and insurers.
• GLP-1 users seeking diet insights.
• Potential lactate monitoring users.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Cost Structure

You're looking at the hard costs Nemaura Medical Inc. faces to keep the sugarBEAT platform moving from development to commercial scale. It's a mix of heavy upfront investment in science and ongoing costs for manufacturing and market access. Here's the quick math on where the money goes, based on the latest reported figures and forward-looking regulatory costs.

High Research and Development (R&D) expenses

Research and Development expenses are a significant drain, reflecting the need to refine the technology and support ongoing regulatory submissions. For the fiscal year ended March 31, 2023, Nemaura Medical Inc. reported R&D expenses of approximately $1,538,615. Management had anticipated that spending in this area would remain reasonably consistent in the fiscal year following that report.

Manufacturing costs for the disposable sugarBEAT sensors and rechargeable transmitters

The cost structure includes scaling production for both the disposable sensors and the rechargeable transmitters. Nemaura Medical Inc. outsources manufacturing, working with a partner, Nemaura Pharma, to scale up component manufacturing and final assembly in the UK. Additionally, the electronic transmitter manufacturing is supported by a contract manufacturing partner, Benchmark Electronics Inc., at their facility in Thailand, which is FDA approved.

While specific unit costs for Nemaura Medical Inc. aren't public, the operational setup involves significant commitment to contract manufacturing agreements:

Cost Component Area	Associated Partner/Location	Relevant Financial Data Point
Sensor/Transmitter Scale-up	Nemaura Pharma (UK)	Costs and timing of developing a commercial scale manufacturing facility are key variables.
Transmitter Manufacturing	Benchmark Electronics Inc. (Thailand)	Focus on facilitating future volume scale-up manufacture.
General Market Cost Proxy (Metabolite Patch)	Global Market Data (2024)	Implied Cost-of-Goods-Sold per unit of $37,500 (based on a market ASP of $50,000 per K unit and 25% gross margin)

Sales, General, and Administrative (SG&A) costs to support global commercialization efforts

Supporting commercialization, especially in the EU where CE mark approval is secured, drives up the General and Administrative portion of operating expenses. For the three months ended June 30, 2023, Nemaura Medical Inc. reported General and Administrative expenses of $1,508,467. These costs cover the infrastructure needed to support sales, distribution, and general corporate functions.

Significant regulatory compliance and clinical trial costs (e.g., FDA PMA process)

Navigating the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) process is a major, non-recurring, but substantial cost center. Nemaura Medical Inc. submitted its PMA application in July 2020. Based on the FDA User Fees for Fiscal Year 2026 (effective October 1, 2025), the costs associated with maintaining this regulatory status or filing future submissions are concrete figures you must budget for:

• Standard FDA PMA Application Fee (FY 2026): $579,272
• Small Business Fee for PMA Application (FY 2026): $144,818
• Annual Fee for Periodic Reporting on a Class III device (PMA) (FY 2026): $20,275 (Standard) or $5,069 (Small Business)

If Nemaura Medical Inc. qualifies for the Small Business Determination (SBD) program, they may be eligible for a waiver on the first PMA application fee, but the annual reporting fees are still a recurring compliance cost.

Marketing and customer acquisition costs for the subscription-based digital programs

The digital programs, like proBEAT™, which combine glucose data with AI processing under a subscription service, involve customer acquisition costs. An initial purchase order from HealthFleet Inc. gives us a view into the value exchange for these programs. This order involved 5,000 proBEAT subscriptions, covering 75,000 glucose sensors over five months, and was valued at $500,000 in revenue.

This suggests that the cost structure must absorb the expense of the disposable sensors within the subscription price, plus the ongoing costs of maintaining the digital platform and coaching services. The total market for wellness applications using this technology was estimated to reach $60 billion by 2023, showing the scale of potential marketing spend required to capture share.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Revenue Streams

You're looking at the core ways Nemaura Medical Inc. (NMRD) brings in cash right now, late in 2025. It's a mix, as you'd expect from a MedTech firm transitioning from development to scale, heavily reliant on product sales and digital service adoption.

The most immediate, concrete financial data point for the near term is the forecast. Honestly, the quarterly revenue picture is still quite lean, reflecting the early commercialization stage. For the third quarter of 2025, the revenue forecast sits around $500K.

The primary engine for the business model is the sale of the sugarBEAT system hardware. This involves two components:

• Sales of the rechargeable transmitter.
• Sales of the disposable sensors.

Beyond the hardware, the recurring revenue component is key, tied to the digital health and coaching services. This is where the long-term value is built, assuming high patient engagement. These streams include:

• Subscription revenue from the proBEAT digital health and coaching services.
• Subscription revenue from the MiBoKo digital health and coaching services.

We also look for larger, less frequent revenue injections from strategic agreements. This covers licensing fees and milestone payments that come from commercial distribution partners as they hit certain targets or secure regional approvals. These are lumpy but important for cash flow.

To give you a snapshot of the B2B side, which can provide significant upfront revenue, you should remember the initial HealthFleet order. This was a firm commitment, valued at $500,000 in revenue, announced back in January 2023. That initial order covered 75,000 proBEAT glucose sensors over a five-month period, showing the potential volume tied to a single partner contract.

Here's a quick look at how these revenue components fit into the overall structure, based on the company's stated model:

Revenue Stream Category	Specific Component	Known Financial Data Point (2023/Forecast)
Product Sales (Hardware)	sugarBEAT System (Transmitter & Sensors)	75,000 sensors in initial HealthFleet order.
Recurring Service Revenue	proBEAT & MiBoKo Subscriptions	Forecasted quarterly revenue of $500K for Q3 2025.
Strategic/Partnership Revenue	Licensing Fees and Milestone Payments	No specific 2025 amounts publicly available.
B2B Initial Orders	HealthFleet Purchase Order	Initial order valued at $500,000.

The company generates revenue primarily from the direct sales of the sugarBEAT system, which includes the sensors and transceivers, aimed at diabetes and pre-diabetes management. Also, revenue is recognized through partnerships with distributors and healthcare providers who integrate sugarBEAT into their service offerings. The focus on digital platforms, like proBEAT, is intended to capture recurring revenue alongside the disposable sensor sales.

Finance: draft 13-week cash view by Friday.